Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Ziconotide (Prialt) peptide icon, one bubble per amino acidZiconotide (Prialt)25 residuesCKGKGAKCSRLMYDCCTGSCRSGKCEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Ziconotide (Prialt)

Healing & RecoveryFDA Approved
4.6 h half-life·Injection

Also known as: Prialt, omega-conotoxin MVIIA, SNX-111

A cone snail venom turned FDA-approved painkiller. Ziconotide (brand name Prialt) is a synthetic 25-amino-acid copy of omega-conotoxin MVIIA, approved in December 2004 for severe chronic pain that nothing else can touch. It blocks N-type calcium channels (Cav2.2) at the spinal cord level, stopping pain signals without binding a single opioid receptor. No tolerance builds over years of continuous use; a 2025 meta-analysis of 23 studies (n=1,531) confirmed a mean pain reduction of 22.54 points versus placebo. The catch is delivery. Ziconotide requires continuous intrathecal infusion through a surgically implanted pump, and psychiatric side effects forced discontinuation in roughly half of real-world patients within two years.

What Is Ziconotide (Prialt)?

A 2025 meta-analysis pooling 23 studies and 1,531 patients landed on a mean pain reduction of 22.54 points versus placebo (p=0.002)[1]. That is the most current aggregate number for ziconotide, an FDA-approved peptide derived from Pacific cone snail venom.

Ziconotide (Prialt, omega-conotoxin MVIIA, CAS 107452-89-1) is a synthetic 25-amino-acid peptide with three disulfide bonds. The FDA approved it in December 2004 for severe chronic pain in patients who have failed or cannot tolerate other analgesic options, including intrathecal morphine.

The mechanism is selective Cav2.2 calcium channel blockade at the spinal cord dorsal horn. By physically occluding these channels on nociceptive nerve terminals, ziconotide prevents release of glutamate, CGRP, and substance P. Pain signals stop before reaching the brain. No opioid receptors are involved, so respiratory depression and tolerance are absent.

Three important RCTs built the approval case. Study 96-002 (Wallace et al.)[2] showed 31.2% mean pain reduction versus 6.0% for placebo in 255 patients. Study 301 (Rauck et al.)[3] confirmed efficacy with slower titration in 220 patients. A long-term open-label extension tracked 644 patients over 350 patient-years of sustained relief (Wallace et al.)[4].

Real-world outcomes tell a more complicated story. The PRIZM registry (n=93) recorded about 50% of patients achieving 30% or greater pain reduction at 12 months. Psychiatric side effects, including hallucinations (12%), psychosis (1%), and insidious cognitive decline, drove high discontinuation rates. Only about 4 of 15 patients remained on therapy at two years in one cohort. The 2024 PACC guidelines now recommend starting at 0.5 to 1.0 mcg/day, well below the FDA label's 2.4 mcg/day, because slower titration dramatically reduces CNS adverse events.

How Ziconotide (Prialt) Works

Three disulfide bonds lock ziconotide into a rigid three-dimensional structure. That shape is what makes it fit the Cav2.2 calcium channel pore like a plug. The peptide binds the extracellular surface of the alpha-1B subunit and physically blocks calcium ions from flowing through.

Cav2.2 channels sit densely on nociceptive nerve terminals in laminae I and II of the spinal cord dorsal horn. When calcium can't enter those terminals, vesicular release of excitatory neurotransmitters stops. Glutamate, CGRP, and substance P all stay locked in their presynaptic vesicles. The first central synapse in the pain pathway goes quiet.

Selectivity is the pharmacological headline. Ziconotide has zero affinity for mu, delta, or kappa opioid receptors. It also ignores adrenergic, serotonin, dopamine, and GABA receptors. This explains why opioid side effects (respiratory depression, constipation, escalating tolerance) simply don't occur. There is no receptor downregulation or compensatory upregulation pathway with Cav2.2 blockade; tolerance does not develop over months or years.

The same Cav2.2 channels also exist in supraspinal brain regions that regulate cognition, mood, and motor function. Blocking them there produces the dose-limiting neuropsychiatric toxicity: confusion, hallucinations, memory impairment, and psychosis. That overlap between therapeutic target and toxicity target creates the narrow therapeutic window that makes ziconotide so difficult to dose.

Ziconotide (Prialt) Benefits

  • Ziconotide benefits center on non-opioid analgesia for the most refractory chronic pain cases.
  • Zero tolerance development over years of continuous therapy. Unlike intrathecal opioids, dose requirements stay flat indefinitely because Cav2.2 blockade has no receptor desensitization pathway.
  • Pain reduction of 22.54 points versus placebo across 1,531 patients in a 2025 meta-analysis (Picañol et al.)[1].
  • No respiratory depression, no constipation, no physical dependence. Stopping abruptly causes pain return, not opioid withdrawal.
  • Study 96-002 (n=255) recorded 31.2% mean pain reduction with rapid titration [2]. Study 301 (n=220) confirmed efficacy under slow titration [3].
  • Sustained long-term relief confirmed in a 644-patient open-label extension spanning 350 patient-years [4].
  • PRIZM real-world registry showed approximately 50% of patients reaching 30% or greater pain relief at 12 months, holding without dose escalation.

Ziconotide (Prialt): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

FDA-approved (2004) for severe refractory chronic pain via continuous intrathecal infusion.

Dosing studied: 0.5–19.2 mcg/day IT continuous infusion. 2024 PACC guidelines recommend starting 0.5–1.0 mcg/day; FDA label allows up to 2.4 mcg/day start; maximum 19.2 mcg/day.
Read the evidence (key study, limitations)

Three pivotal RCTs established efficacy. 2025 meta-analysis (n=1,531, 23 studies) confirmed mean pain reduction of −22.54 points vs placebo (p=0.002). No pharmacological tolerance. Serious AE rate 17.85% (2.63× placebo). Confined to tertiary pain management settings requiring surgical pump implantation.

Key Study

Picañol et al. Pain Rep 2025 (PMID 41255849): meta-analysis 23 studies n=1,531; also SPIDOL RCT protocol (Trials 2024, PMID 39244617) for SCI neuropathic pain.

Limitations

Pivotal RCTs used faster titration than current clinical best practice; high AE-driven dropout rates inflate discontinuation figures; intrathecal-only delivery severely limits applicability; real-world PRIZM registry shows ~50% ≥30% responder rate at 12 months, lower than RCT estimates.

Community Experience
Moderate
2.5/5
Based on Drugs.com n=11 reviews

Mixed-to-negative overall sentiment (Drugs.com 4.3/10, 27% positive, 45% negative).

Community dosing: 2–7 mcg/day in long-term real-world use; median ~5.5–7.2 mcg/day per PRIZM registry (n=93)
Read the reports (what users report 3, common issues 5)

Those who tolerate it describe meaningful, sustained relief. Most negative reports center on severe CNS adverse effects. High real-world discontinuation: only ~4/15 patients still on drug at 2 years in one cohort.

What users report (3)
  • Non-opioid analgesia: no tolerance, no respiratory depression, no physical dependence or withdrawal
  • Meaningful sustained pain relief for truly refractory patients (CRPS, FBSS, cancer pain) who have failed all other options
  • Long-term efficacy without dose escalation, unlike intrathecal opioids
Common issues (5)
  • Severe cognitive impairment: memory loss, word-finding difficulty, confusion, often insidious in onset
  • Hallucinations, psychosis, depression; psychiatric AEs can appear weeks after dose change
  • Invasive delivery requiring surgical pump implantation under specialist care
  • Very high real-world discontinuation rate; many patients cannot tolerate effective analgesic doses
  • Recurrent psychiatric AEs on rechallenge documented (PMID 40511848)
Partially Aligned

Both science and community confirm analgesic efficacy for refractory pain. Divergence on tolerability: clinical trials underestimate real-world CNS AE burden and discontinuation rates. The 2024 PACC guideline shift to 0.5 mcg/day starting dose (vs. FDA label 2.4 mcg/day) reflects this community-driven understanding that slower titration dramatically improves real-world tolerability.

Ziconotide (Prialt) Dosage Guide

FDA LabelPrialt (ziconotide) intrathecal infusion FDA Prescribing Information (2011)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner2.4 mcgDaily
Moderate9.6 mcgDaily
Aggressive19.2 mcgDaily
Note:

Ziconotide ships as a pre-filled solution, not a lyophilized powder. No reconstitution with bacteriostatic water is needed. The two concentrations are 25 mcg/mL and 100 mcg/mL.

Delivery math for the 25 mcg/mL formulation in a 20 mL vial: 500 mcg total per vial. At a maintenance dose of 5 mcg/day, that is a 100-day supply per pump refill. The 100 mcg/mL concentration must be diluted with preservative-free normal saline (not bacteriostatic water) when used in external pumps.

The FDA label says you can start at 2.4 mcg/day. Most pain specialists don't anymore. The 2024 PACC consensus guidelines recommend 0.5 to 1.0 mcg/day with increases no larger than 0.5 mcg/day per week. That slower ramp cuts psychiatric and cognitive side effects dramatically compared to the FDA-label titration speed.

Your pump refill schedule depends on concentration, flow rate, and reservoir size. Typical intervals run every 1 to 3 months. Every refill visit should include cognitive screening, psychiatric assessment, orthostatic blood pressure, and CK levels.

Cycling

Ziconotide is used as continuous long-term therapy delivered via intrathecal pump, not cycled. Treatment is maintained indefinitely as long as the patient derives analgesic benefit and tolerates the medication. Dose adjustments are made gradually: no more than 2.4 mcg/day increases, no more frequently than 2-3 times per week. If discontinued, no taper is required as there is no physical dependence or withdrawal syndrome. Treatment may be interrupted or discontinued if psychiatric symptoms, cognitive impairment, or elevated CK levels occur.

Calculate your Ziconotide (Prialt) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Ziconotide (Prialt) Protocols by Goal

advancedFDA LabelIndefinite (continuous long-term therapy)
Initiation
Wk Day 1
0.5–1.0 mcg/day (2024 PACC preferred) or up to 2.4 mcg/day (0.1 mcg/hr; FDA label maximum start) · Continuous IT infusion via implanted or external microinfusion pump · Intrathecal
Titration
Wk Weeks 1–8+ (rate varies by protocol)
Increase ≤2.4 mcg/day per step at ≤2–3× per week (FDA label) OR ≤0.5 mcg/day per step weekly (2024 PACC preferred) · Dose adjustments at clinical visits; infusion itself is continuous 24 hr/day · Intrathecal
Maintenance
Wk Indefinite (long-term continuous therapy)
Individualized effective dose; mean 6.9–9.6 mcg/day in pivotal trials; real-world 2–7 mcg/day (PRIZM); FDA maximum 19.2 mcg/day (0.8 mcg/hr) · Continuous IT infusion; pump refills every 1–3 months depending on concentration and flow rate · Intrathecal

Expected: ≥30% pain reduction in ~50% of patients at 12 months (PRIZM real-world); −22.54 mean VAS/NRS reduction vs placebo in meta-analysis; 31.2% mean pain reduction in pivotal Study 96-002 (rapid titration arm)

Monitor: CK every 2 weeks for first month, then monthly. MMSE or MoCA at every visit (baseline required). Psychiatric assessment each visit. Orthostatic BP at each pump refill.

How to Inject Ziconotide (Prialt)

  1. 1
    Step 1

    Ziconotide requires a Medtronic SynchroMed II implantable intrathecal pump or an external microinfusion device with intrathecal catheter. This is not a subcutaneous, intravenous, or epidural medication.

  2. 2
    Step 2

    A qualified healthcare provider fills the pump reservoir under strict sterile conditions. The 25 mcg/mL solution can go in undiluted. The 100 mcg/mL solution gets diluted with preservative-free 0.9% NaCl to the target concentration.

  3. 3
    Step 3

    Starting dose is 0.5 to 1.0 mcg/day per 2024 PACC guidelines (or up to 2.4 mcg/day per the FDA label). The pump delivers this continuously over 24 hours, not as a bolus. At 1.0 mcg/day, the pump flow rate is approximately 0.042 mcg/hour.

  4. 4
    Step 4

    Titration: increase by no more than 0.5 mcg/day per week (PACC preferred) or 2.4 mcg/day no more than 2 to 3 times per week (FDA maximum titration rate). Each dose adjustment requires a clinical visit.

  5. 5
    Maximum recommended dose is 19.2 mcg/day (0.8 mcg/hour)

    Most patients find an effective maintenance dose between 2 and 9.6 mcg/day; the PRIZM registry median landed around 5.5 to 7.2 mcg/day.

  6. 6
    Step 6

    Monitoring at every visit: MMSE or MoCA for cognitive function, psychiatric screening, orthostatic blood pressure. CK levels every 2 weeks for the first month, then monthly. Any new psychiatric symptom triggers a dose hold.

  7. 7
    Storage: refrigerate at 2 to 8 degrees Celsius

    Undiluted vials can sit at room temperature (up to 25 degrees Celsius) for up to 14 days. Once in the pump, use within 84 days refrigerated or 40 days at body temperature.

Ziconotide (Prialt) Stacking Protocols

Works With

Intrathecal Morphine

Most studied IT combination with ziconotide; complementary mechanisms (opioid + Cav2.2 blockade); used off-label for refractory cancer and non-cancer pain. Admixture stability confirmed up to ~20 days.

Combination IT pump; individual doses titrated independently. Admixture prepared by pharmacy.

Intrathecal Clonidine

Complementary mechanism (alpha-2 adrenergic); good admixture stability (~90% at 60 days at clonidine 2 mcg/mL + ziconotide). Preferred combination for neuropathic pain per PACC.

Clonidine 2 mcg/mL + ziconotide in combination IT pump; monitor for additive hypotension.

Intrathecal Hydromorphone

Alternative to morphine for opioid-intolerant patients; case reports in spinal cord injury neuropathic pain (PMID 17310258).

Avoid

CNS Depressants (benzodiazepines, sedatives, antiepileptics)

Additive CNS depression: increased dizziness, confusion, somnolence. FDA-labeled drug interaction.

Neuroleptics / Antipsychotics

Increased risk of psychiatric AEs and depressed consciousness when combined with ziconotide. FDA-labeled interaction.

Diuretics

Patients on diuretics are at higher risk of depressed level of consciousness per FDA label.

Statins / Fibrates (CK-elevating drugs)

Confound mandatory CK monitoring; may amplify rhabdomyolysis risk signal. Use with caution and increased CK monitoring frequency.

Estimated Cost

Brand Price
Prialt 25 mcg/mL 20 mL vial (500 mcg): ~$5,829. Prialt 100 mcg/mL 1 mL vial (100 mcg): ~$810. Prialt 100 mcg/mL 5 mL vial (500 mcg): ~$3,904. Medicare J2278 reimbursement ~$10.46/mcg unit (Q2 2026). Manufacturer co-pay program: as low as $20/fill for commercially insured patients (up to $8,000/year savings). Brand-only: no generic available as of October 2026 (Drugs@FDA).

Pricing updated 2026-04-09

Ziconotide (Prialt) Side Effects

Black Box Warning: severe psychiatric symptoms and neurological impairment. This is the lead safety concern, not a footnote. Hallucinations hit 12% of trial patients. Psychosis occurred in 1%. Depression with suicidal ideation has been reported. Documented cases of psychiatric recurrence on rechallenge exist [5], meaning once ziconotide triggers psychosis, restarting it is not safe.

Cognitive impairment is the most insidious problem. Word-finding difficulty, memory loss, and confusion affected 7 to 22% of patients in clinical trials. The onset can be gradual enough that patients or families don't recognize the decline for weeks. Formal cognitive screening (MMSE or MoCA) at every visit catches what casual conversation misses. Any new cognitive symptom within weeks of a dose increase should be attributed to ziconotide until proven otherwise.

Dizziness was the single most common adverse event at 47%. Nausea reached 30%. Confusion hit 33%. Somnolence affected 22%. Abnormal gait (14%), nystagmus (8%), and visual disturbances also appeared in important trials. Most of these track directly with dose; slower titration per the 2024 PACC guidelines (0.5 mcg/day increases weekly instead of the FDA-label rate) substantially reduces incidence.

CK elevation occurred in 10 to 40% of patients. Levels above 3 times the upper limit of normal require dose reduction or hold. Investigate for rhabdomyolysis symptoms (dark urine, muscle pain) if CK spikes.

Meningitis, both chemical and bacterial, has been reported in patients using external microinfusion devices. Strict aseptic technique during pump refills is non-negotiable.

Postural hypotension, urinary retention, fever, and asthenia round out the profile. The serious adverse event rate across the meta-analysis was 17.85%, roughly 2.6 times the placebo rate.

Contraindications: preexisting psychosis (FDA-labeled), active suicidal ideation, severe untreated depression, spinal canal obstruction, uncontrolled bleeding diathesis, active infection at the pump site, pregnancy (Category C), and breastfeeding. When to seek immediate medical attention: new hallucinations, suicidal thoughts, sudden cognitive decline, high-grade fever with neck stiffness, or dark urine with muscle pain.

Common Issues & Solutions

Cognitive fog / memory impairment: Reduce dose by at least 50% immediately. Do not attribute new cognitive symptoms to the patient's baseline condition without ruling out ziconotide first: timing relative to dose changes is the key discriminator. Symptoms typically resolve within days of dose reduction.

Hallucinations or psychosis: Hold dose escalation; consider dose reduction or discontinuation. If frank psychosis, discontinue immediately. Documented recurrence on rechallenge [5]: do not rechallenge in patients with ziconotide-induced psychosis.

Nausea and dizziness on initiation: Dose-dependent and usually transient. Slow PACC titration (≤0.5 mcg/day/week) substantially reduces incidence vs. FDA-label titration rate. Anti-emetics may help short-term but do not treat the underlying dose issue.

CK elevation >3× ULN: Reduce or hold dose; investigate for clinical signs of rhabdomyolysis (myalgias, dark urine). Do not restart until CK normalizes and cause is clarified. Do not increase statin dose during ziconotide therapy without increased CK monitoring.

Abrupt return of pain (suspected pump failure): Pump malfunction or catheter dislodgement mimics treatment failure: check pump function, catheter integrity, and CSF drug levels before assuming inadequate dose. There is no withdrawal syndrome; abrupt pain return is loss of analgesic coverage, not rebound.

Ask AI about this page

Ask AI for a second opinion on Ziconotide (Prialt) dosing and side effects

Contraindications

  • Preexisting history of psychosis (FDA-labeled contraindication)
  • Hypersensitivity to ziconotide or any component of the formulation
  • Active infection at the microinfusion injection site
  • Uncontrolled bleeding diathesis or concurrent anticoagulation with spinal canal risk
  • Spinal canal obstruction that impairs CSF circulation
  • Active suicidal ideation or severe untreated depression
  • Pregnancy (Category C: potential for fetal harm based on animal studies)
  • Breastfeeding (unknown excretion in human milk; not recommended)

Drug Interactions

  • CNS depressants (benzodiazepines, sedatives, antiepileptics): Additive CNS depression including increased dizziness, confusion, and somnolence; monitor closely and consider dose reduction of concomitant agents
  • Intrathecal opioids: Combination not studied in controlled trials and not recommended; potential for additive CNS effects
  • Neuroleptics/antipsychotics: Increased risk of psychiatric adverse events and depressed consciousness; use with caution
  • Intrathecal clonidine or bupivacaine: May potentiate hypotensive effects of ziconotide
  • Drugs that elevate CK (statins, fibrates): May complicate monitoring of CK levels, which is recommended during ziconotide therapy
  • Diuretics: Patients taking concomitant diuretics may be at higher risk of depressed levels of consciousness
  • Additive CNS depression: increased dizziness, confusion, somnolence. FDA-labeled drug interaction.

Product Quality

Recommended Monitoring

TestWhenTarget
Creatine Kinase (CK / CPK)Every 2 weeks for first month; monthly thereafter<3× ULN; reduce or hold dose if >3× ULN; investigate clinically for rhabdomyolysis symptoms
Cognitive Assessment (MMSE or MoCA)Baseline before initiation required; every clinical visit during titration and maintenanceSignificant decline from individual baseline warrants dose reduction or discontinuation
Psychiatric EvaluationBaseline (mandatory: psychosis is FDA contraindication); every visit; urgently with any new psychiatric symptomAny new hallucinations, psychosis, or suicidal ideation → dose reduction or discontinuation
Blood Pressure (orthostatic)Each pump refill visitNot listed
CSF AnalysisIf fever, headache, or neck stiffness develop: especially in patients with external pumpNot listed
Creatine Kinase (CK / CPK)

Rhabdomyolysis risk documented in clinical trials; CK elevation common (10–40% of patients)

Cognitive Assessment (MMSE or MoCA)

Ziconotide-induced cognitive impairment can be insidious; formal baseline enables objective comparison

Psychiatric Evaluation

Black Box Warning: hallucinations (12%), psychosis (1%), depression with suicidal ideation; symptoms can emerge weeks after dose change

Blood Pressure (orthostatic)

Postural hypotension reported; additive risk if combined with IT clonidine, systemic diuretics, or antihypertensives

CSF Analysis

Chemical meningitis and bacterial meningitis both reported; external devices carry highest risk; requires urgent evaluation and lumbar puncture

Ziconotide (Prialt) Before and After

Day 1
initiation

Intrathecal infusion begins at 2.4 mcg/day (0.1 mcg/hour). Steady-state CSF concentration is approximated within ~24 hours (approximately five half-lives). Some patients may notice early pain relief within hours. Common initial side effects include dizziness, nausea, and somnolence.

Weeks 1-3
titration

Gradual dose escalation in increments of no more than 2.4 mcg/day, no more than 2-3 times per week. Pain relief increases with dose. Cognitive side effects (confusion, memory impairment) and psychiatric symptoms may emerge during this period: careful monitoring is essential.

Weeks 3-6
stabilization

Most patients reach an effective maintenance dose, typically between 4.8-14.4 mcg/day in clinical practice. In pivotal trials, mean effective doses ranged from 6.9-9.6 mcg/day. CK levels should be monitored every other week.

Months 2-6

Sustained analgesia at stable dose. Unlike opioids, tolerance does not develop. Ongoing monitoring for insidious cognitive changes, mood disturbances, and psychiatric symptoms is critical. CK monitoring transitions to monthly.

Months 6-12+

Long-term maintenance with continued efficacy. Pump refills every 1-3 months depending on concentration and flow rate. Long-term open-label data shows sustained pain relief over 350+ patient-years. Periodic neuropsychological assessment is recommended.

What to Expect

Day 1 to 7 (Initiation): Intrathecal infusion starts at 0.5 to 2.4 mcg/day depending on protocol. CSF steady-state concentration arrives within roughly 24 hours (about five half-lives at 4.6 hours CSF t1/2). Some patients notice partial pain relief within hours. Dizziness (47% in trials), nausea (30%), and somnolence (22%) are the dominant early side effects. Most side effect tolerance improves within the first week.

Weeks 1 to 8 (Titration): Dose climbs in incremental steps. PACC slow titration (0.5 mcg/day increases weekly) is preferred in clinical practice over the faster FDA-label schedule. Psychiatric and cognitive adverse events are most likely to surface or worsen during active escalation. Fast titration produced 53.1% pain reduction in trials but carried very high side effect burden. Community and clinical experience consistently favor the slower approach. Confusion (33%), memory impairment (7 to 22%), nystagmus (8%), abnormal gait (14%), and visual changes are the main concerns during this phase.

Months 2 to 6 (Stabilization): Most patients reach an effective maintenance dose, typically between 2 and 9.6 mcg/day. The PRIZM registry recorded a median of 5.5 to 7.2 mcg/day in real-world use. No tolerance develops, so dose requirements stay stable indefinitely. High discontinuation occurs at this stage from delayed-onset cognitive impairment that patients or families only recognize retrospectively. PRIZM data showed about 50% of patients achieving 30% or greater pain relief at month 12.

Months 6 to 24 and beyond (Long-term Maintenance): Sustained pain relief without dose escalation is the defining advantage over intrathecal opioids. The open-label extension (n=644) confirmed continued efficacy over 350 patient-years. Pump refills run every 1 to 3 months. Long-term users describe it as transformative for refractory pain but acknowledge cognitive costs at higher doses. Real-world attrition is steep; roughly 4 of 15 patients remained on therapy at two years in one cohort. External pump users face ongoing meningitis risk from both chemical and bacterial sources.

Detailed Timeline: Science vs Community

Day 1–7 (Initiation)
Science

CSF steady-state achieved within ~24 hours (~5 half-lives at 4.6 hr CSF t½). Some patients report early partial pain relief within hours.

Community

Mixed first impressions: some notice relief quickly; many experience prominent side effects (dizziness, nausea, sedation) before meaningful pain benefit. Tolerance to side effects often improves within first week.

Weeks 1–8 (Titration)
Science

Incremental pain reduction with each dose step. Psychiatric and cognitive AEs most likely to emerge or worsen during active titration. Fast titration (FDA-label rate) associated with 53.1% pain reduction but very high AE burden.

Community

PACC slow titration (≤0.5 mcg/day/week) consistently preferred in clinical practice. Patients on rapid titration report high rates of cognitive "fog" and psychiatric symptoms. Many discontinue during this phase.

Months 2–6 (Stabilization)
Science

Most patients reach effective maintenance dose (2–9.6 mcg/day in trials; 2–7 mcg/day real-world). No tolerance development: dose requirements stable indefinitely.

Community

Those who tolerate it report meaningful sustained relief. High discontinuation at this stage due to delayed-onset cognitive impairment that patients or families recognize only retrospectively. PRIZM registry: 50% ≥30% responders at Month 12.

Months 6–24+ (Long-term Maintenance)
Science

Sustained efficacy without dose escalation: key advantage over intrathecal opioids. Long-term OLE (n=644, 350+ patient-years) confirms continued pain relief. Pump refills every 1–3 months.

Community

Long-term survivors describe it as life-changing for refractory pain but acknowledge significant cognitive cost at higher doses. Real-world attrition: ~4/15 patients still on drug at 2 years in one cohort. External pump users face ongoing meningitis risk.

Pharmacokinetics

Half-Life
4.6h
Bioavailability
Intrathecal: 100% (direct CSF delivery); negligible systemic exposure
Tmax
Continuous infusion: steady-state CSF concentration achieved within ~24 hours
Data Confidence
high

Source: FDA prescribing information; Wermeling D et al. J Clin Pharmacol. 2003;43(6):624-36. PMID: 12817525 (median 4.5 h in CSF, range 2.9-6.5 h)

Pharmacokinetics: Active Dose Over Time

t½ = ~4.6 hours (CSF); ~1.3 hours (serum)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
25
Sequence
CKGKGAKCSRLMYDCCTGSCRSGKC
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Ziconotide (Prialt)

  • Patients with severe chronic pain refractory to systemic analgesics and adjunctive therapies
  • Individuals intolerant of or refractory to intrathecal morphine
  • Patients with severe neuropathic pain (e.g., from spinal cord injury, failed back surgery syndrome)
  • Cancer patients with intractable pain who have failed conventional analgesic ladders
  • Patients requiring non-opioid intrathecal analgesia due to opioid tolerance or adverse effects
  • Adults with chronic pain who already have or are candidates for implanted intrathecal pump systems

Related Peptides

What Changed for Ziconotide (Prialt)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations

References

  1. [1]Efficacy and safety of the Cav2.2 blocker ziconotide in pain: a meta-analysis and systematic review (Picanol et al., Pain Rep 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Recurrent ziconotide-associated delirium and psychosis: a case report (Noe et al., J Clin Psychopharmacol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as pre-filled solution, not lyophilized
After Reconstitution
Refrigerate at 2-8°C (36-46°F). Stable at room temperature (up to 25°C) for 24 hours when in the pump. Undiluted solution in vial may be stored at room temperature for up to 14 days. Once transferred to microinfusion pump, use within 84 days if refrigerated or 40 days at 37°C.
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

The FDA label says this combination wasn't studied in controlled trials and is not recommended. Some pain management specialists have used combination pumps off-label, but the risk of additive CNS side effects is significant. The PACC consensus guidelines generally recommend ziconotide as monotherapy when it's the first-line intrathecal choice.

This is a genuine clinical challenge. Ziconotide-induced psychiatric symptoms can be insidious and mimic depression, early dementia, or delirium. The key indicator is timing relative to dose changes. A structured cognitive screen (MMSE or MoCA) should be done at every visit. Any new psychiatric symptom within weeks of a dose increase should be attributed to ziconotide until proven otherwise: symptoms typically resolve with dose reduction.

Unlike opioids, ziconotide causes no physical dependence and no withdrawal syndrome. It can be stopped abruptly without tapering. The catch: baseline pain returns, which may need urgent alternative pain management. Pump malfunction causes sudden pain return (not withdrawal), requiring urgent clinical attention.

Rarely. In pivotal trials, mean effective doses ranged from 6.9-9.6 mcg/day. Many patients get adequate pain relief well below the maximum and are limited by side effects, particularly dizziness and cognitive impairment, before getting anywhere near 19.2 mcg/day. Slower titration than the FDA's maximum rate is common in clinical practice.

Ziconotide's biggest advantage is no tolerance: dose requirements don't escalate over years. Intrathecal opioids (especially morphine) develop tolerance requiring ongoing dose increases that eventually hit limits. The trade-off: ziconotide has a much narrower therapeutic window with more psychiatric and neurological side effects than low-dose intrathecal opioids. Most guidelines position them as co-equal first-line options, not one better than the other for all patients.